Improving treatment for acute ischemic stroke-Clot busting innovation in the pipeline

Joanna Shu Ting Liu; Yiran Ding; Simone Schoenwaelder; Xuyu Liu

doi:10.3389/fmedt.2022.946367

Improving treatment for acute ischemic stroke-Clot busting innovation in the pipeline

Front Med Technol. 2022 Aug 1:4:946367. doi: 10.3389/fmedt.2022.946367. eCollection 2022.

Authors

Joanna Shu Ting Liu^{1

2}, Yiran Ding³, Simone Schoenwaelder^{1

2}, Xuyu Liu^{1

3}

Affiliations

¹ Heart Research Institute, The University of Sydney, Sydney, NSW, Australia.
² Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.
³ Faculty of Science, School of Chemistry, The University of Sydney, Sydney, NSW, Australia.

Abstract

Acute ischemic stroke is a consequence of disrupted blood flow to the brain, caused by thrombosis-the pathological formation of occlusive clots within blood vessels, which can embolize distally to downstream tissues and microvasculature. The highest priority of stroke treatment is the rapid removal of occlusive clots and restoration of tissue perfusion. Intravenous thrombolysis is the pharmacological standard-of-care for the dissolution of blood clots, wherein thrombolytic drugs are administered to restore vessel patency. While the introduction of recombinant tissue-plasminogen activator (rtPA) in 1996 demonstrated the benefit of acute thrombolysis for clot removal, this was countered by severe limitations in terms of patient eligibility, lytic efficacy, rethrombosis and safety implications. Development of safer and efficacious treatment strategies to improve clot lysis has not significantly progressed over many decades, due to the challenge of maintaining the necessary efficacy-safety balance for these therapies. As such, rtPA has remained the sole approved acute therapeutic for ischemic stroke for over 25 years. Attempts to improve thrombolysis with coadministration of adjunct antithrombotics has demonstrated benefit in coronary vessels, but remain contraindicated for stroke, given all currently approved antithrombotics adversely impact hemostasis, causing bleeding. This Perspective provides a brief history of stroke drug development, as well as an overview of several groups of emerging drugs which have the potential to improve thrombolytic strategies in the future. These include inhibitors of the platelet receptor glycoprotein VI and the signaling enzyme PI3-Kinase, novel anticoagulants derived from hematophagous creatures, and proteolysis-targeting chimeras.

Keywords: PI3K; PROTACs; anticoagulants; antiplatelets; targeted degradation; thrombolysis (for acute ischaemic stroke); tick-derived salivary proteins/peptides; tissue plasminogen activator.